118 related articles for article (PubMed ID: 37011969)
1. Translational study for stereotactic body radiotherapy against non-small cell lung cancer, including oligometastases, considering cancer stem-like cells enable predicting clinical outcome from in vitro data.
Saga R; Matsuya Y; Sato H; Hasegawa K; Obara H; Komai F; Yoshino H; Aoki M; Hosokawa Y
Radiother Oncol; 2023 Apr; 181():109444. PubMed ID: 37011969
[TBL] [Abstract][Full Text] [Related]
2. Optimal Radiation Therapy Fractionation Regimens for Early-Stage Non-Small Cell Lung Cancer.
Liu F; Ververs JD; Farris MK; Blackstock AW; Munley MT
Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):829-838. PubMed ID: 37734445
[TBL] [Abstract][Full Text] [Related]
3. Calculating the individualized fraction regime in stereotactic body radiotherapy for non-small cell lung cancer based on uncomplicated tumor control probability function.
Lu JY; Lin PX; Huang BT
Radiat Oncol; 2019 Jun; 14(1):111. PubMed ID: 31221159
[TBL] [Abstract][Full Text] [Related]
4. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
[TBL] [Abstract][Full Text] [Related]
5. Revisiting the formalism of equivalent uniform dose based on the linear-quadratic and universal survival curve models in high-dose stereotactic body radiotherapy.
Chan MKH; Chiang CL
Strahlenther Onkol; 2021 Jul; 197(7):622-632. PubMed ID: 33245378
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiation therapy for stage I non-small cell lung cancer: The importance of treatment planning algorithm and evaluation of a tumor control probability model.
Ohri N; Tomé W; Kalnicki S; Garg M
Pract Radiat Oncol; 2018; 8(2):e33-e39. PubMed ID: 29233523
[TBL] [Abstract][Full Text] [Related]
7. Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer.
Huang BT; Lin Z; Lin PX; Lu JY; Chen CZ
Oncotarget; 2016 Jun; 7(26):40746-40755. PubMed ID: 27203739
[TBL] [Abstract][Full Text] [Related]
8. Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans.
Liang X; Penagaricano J; Zheng D; Morrill S; Zhang X; Corry P; Griffin RJ; Han EY; Hardee M; Ratanatharathom V
Radiat Oncol; 2016 Jan; 11():10. PubMed ID: 26800883
[TBL] [Abstract][Full Text] [Related]
9. Treatment fractionation for stereotactic radiotherapy of lung tumours: a modelling study of the influence of chronic and acute hypoxia on tumour control probability.
Lindblom E; Antonovic L; Dasu A; Lax I; Wersäll P; Toma-Dasu I
Radiat Oncol; 2014 Jun; 9():149. PubMed ID: 24974778
[TBL] [Abstract][Full Text] [Related]
10. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
[TBL] [Abstract][Full Text] [Related]
11. Individualized Fraction Regimen of SBRT Patients With Non-Small Cell Lung Cancer Based on Uncomplicated and Cancer-Free Control Probability.
Feng AH; Wang H; Chen H; Gu HL; Shao Y; Duan YH; Huang Y; Fu XL; Zhou T; Xu ZY
Technol Cancer Res Treat; 2021; 20():15330338211011967. PubMed ID: 33982619
[TBL] [Abstract][Full Text] [Related]
12. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
Niibe Y; Nishimura T; Inoue T; Karasawa K; Shioyama Y; Jingu K; Shirato H
BMC Cancer; 2016 Aug; 16(1):659. PubMed ID: 27542716
[TBL] [Abstract][Full Text] [Related]
13. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC).
Lucas JT; Kuremsky JG; Soike M; Hinson WW; Kearns WT; Hampton CJ; Blackstock AW; Urbanic J
Lung Cancer; 2014 Jul; 85(1):59-65. PubMed ID: 24813936
[TBL] [Abstract][Full Text] [Related]
14. Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer.
Cong Y; Sun B; Wang J; Meng X; Xuan L; Zhang J; Liu J; Shen G; Wu S
Thorac Cancer; 2019 Jul; 10(7):1567-1575. PubMed ID: 31187604
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
[TBL] [Abstract][Full Text] [Related]
16. Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models.
Liu F; Tai A; Lee P; Biswas T; Ding GX; El Naqa I; Grimm J; Jackson A; Kong FS; LaCouture T; Loo B; Miften M; Solberg T; Li XA
Radiother Oncol; 2017 Feb; 122(2):286-294. PubMed ID: 27871671
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system.
Katoh N; Soda I; Tamamura H; Takahashi S; Uchinami Y; Ishiyama H; Ota K; Inoue T; Onimaru R; Shibuya K; Hayakawa K; Shirato H
Radiat Oncol; 2017 Jan; 12(1):3. PubMed ID: 28057036
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Single- and Three-fraction Schedules of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-Small-cell Lung Cancer.
Ma SJ; Serra LM; Syed YA; Hermann GM; Gomez-Suescun JA; Singh AK
Clin Lung Cancer; 2018 Mar; 19(2):e235-e240. PubMed ID: 29153897
[TBL] [Abstract][Full Text] [Related]
19. Correlation of clinical outcome, radiobiological modeling of tumor control, normal tissue complication probability in lung cancer patients treated with SBRT using Monte Carlo calculation algorithm.
Sood SS; Pokhrel D; Badkul R; TenNapel M; McClinton C; Kimler B; Wang F
J Appl Clin Med Phys; 2020 Oct; 21(10):56-62. PubMed ID: 32794632
[TBL] [Abstract][Full Text] [Related]
20. A modified hypoxia-based TCP model to investigate the clinical outcome of stereotactic hypofractionated regimes for early stage non-small-cell lung cancer (NSCLC).
Strigari L; Benassi M; Sarnelli A; Polico R; D'Andrea M
Med Phys; 2012 Jul; 39(7):4502-14. PubMed ID: 22830782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
